Diamedica Therapeutics Inc (NASDAQ: DMAC) Speaks Concerning The Phase 2 REDUX Study In CKD And The Associated Positive Interim Results

July 2, 2021

Diamedica Therapeutics Inc (NASDAQ: DMAC) has updated its Phase 2 REDUX Study In CKD. Over the years, this clinical-stage biopharmaceutical company has worked on finding working solutions for cardio-renal diseases and various neurological disorders. The company is quite impressed with the associated Positive Interim Results.  The study’s activities and achievements Today’s announcement tells a lot about its success in its Phase 2 REDUX trial of DM199, a step it considers crucial…

Read More >>